NYSE · NUVB.WS
Nuvation Bio Inc.. Redeemable , each whole exercisable for one of at an exercise price of $11. 50
$0.01 +$0.00 (+24.39%) 1DKey Metrics
$1.73K
Market cap
—
P/E · TTM
$143.05M
Revenue · TTM
−$145.99M
Net income
EPS · TTM
$-431.15
Dividend yield
—
Free cash flow
—
Beta · 1Y
0.59
EBITDA · TTM
—
Gross margin
—
Snapshot
Market cap—
Enterprise value−$486.40M
Shares outstanding—
52-wk range$0.00 – $0.65
Avg volume · 20D21.2K
Net cash
$486.40M
Book value / share$943.75
IndustryPharmaceutical Preparations
ExchangeNYSE
About Nuvation Bio Inc.. Redeemable , each whole exercisable for one of at an exercise price of $11. 50
IPO dateFeb 10, 2021
Employees291
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E—
P/S0.00
P/FCF—
EV/EBITDA—
EV/Sales-3.40
Graham №—
Profitability
Gross
—
Operating
-102.1%
Net
-102.1%
FCF
—
ROE / ROIC
-37.3% · 87.5%
Financial Health
Current ratio7.44
Quick ratio7.24
Debt / equity0.15
Debt / EBITDA
—
Net cash
$486.40M
Working capital$512.01M
Cash Flow · TTM
Operating CF
−$125.73M
Capex
—
Free cash flow
—
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
3 / 9
Weak fundamentals · 3 of 9 signals passing
Altman Z-Score
-2.1
Distress zone (< 1.81) · elevated risk
Graham Number vs Price
—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings